{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=YASMIN&page=2",
    "query": {
      "intervention": "YASMIN",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=YASMIN&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T05:21:03.657Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00420342",
      "title": "Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postmenopause",
        "Hypertension",
        "Pre-Hypertension"
      ],
      "interventions": [
        {
          "name": "Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)",
          "type": "DRUG"
        },
        {
          "name": "SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2007-01",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-02",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 9,
      "location_summary": "Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Paw Paw",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420342"
    },
    {
      "nct_id": "NCT00442689",
      "title": "Metabolic Syndrome in PCOS: Precursors and Interventions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "flutamide",
          "type": "DRUG"
        },
        {
          "name": "ethinyl estradiol 35 mcg and drospirenone 3 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 97,
      "start_date": "2006-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-06-06",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00442689"
    },
    {
      "nct_id": "NCT00651469",
      "title": "Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 45 Years · Female only"
      },
      "enrollment_count": 534,
      "start_date": "2003-01",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2014-12-30",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651469"
    },
    {
      "nct_id": "NCT01182207",
      "title": "Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Drospirenone/Ethinyl Estradiol (Gianvi®)",
          "type": "DRUG"
        },
        {
          "name": "YAZ®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2006-07",
      "completion_date": "2006-08",
      "has_results": true,
      "last_update_posted_date": "2010-12-08",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182207"
    },
    {
      "nct_id": "NCT00283816",
      "title": "Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Oral Contraceptive Pill",
          "type": "DRUG"
        },
        {
          "name": "Lifestyle Management Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Quality of Life Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood work",
          "type": "PROCEDURE"
        },
        {
          "name": "Abdominal Ultra Sound",
          "type": "PROCEDURE"
        },
        {
          "name": "Dual-energy x-ray absorptiometry (DEXA scan)",
          "type": "PROCEDURE"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2006-01",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2015-05-15",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283816"
    },
    {
      "nct_id": "NCT01182194",
      "title": "Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Drospirenone/Ethinyl Estradiol (Gianvi®)",
          "type": "DRUG"
        },
        {
          "name": "YAZ®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2006-06",
      "completion_date": "2006-08",
      "has_results": true,
      "last_update_posted_date": "2010-12-08",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182194"
    },
    {
      "nct_id": "NCT01291004",
      "title": "A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Follicle Development",
        "Ovarian Follicle",
        "Follicle Count",
        "Follicle Size",
        "Oral Contraceptive"
      ],
      "interventions": [
        {
          "name": "Desogestrel/ethinyl estradiol and ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "28-day drospirenone oral contraceptive",
          "type": "DRUG"
        },
        {
          "name": "28-day levonorgestrel oral contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 206,
      "start_date": "2011-01-31",
      "completion_date": "2012-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01291004"
    },
    {
      "nct_id": "NCT00656981",
      "title": "Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 45 Years · Female only"
      },
      "enrollment_count": 541,
      "start_date": "2003-01",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2014-12-30",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 22,
      "location_summary": "Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656981"
    },
    {
      "nct_id": "NCT02885454",
      "title": "To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Drospirenone/ethinylestradiol",
          "type": "DRUG"
        },
        {
          "name": "AL-335",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir (ODV)",
          "type": "DRUG"
        },
        {
          "name": "Simeprevir (SMV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2016-08",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-23",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02885454"
    },
    {
      "nct_id": "NCT00927095",
      "title": "Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Premenstrual Dysphoric Disorder"
      ],
      "interventions": [
        {
          "name": "Continuous OC (EE/DROS)",
          "type": "DRUG"
        },
        {
          "name": "Intermittent OC (EE/DROS)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "52 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 52 Years · Female only"
      },
      "enrollment_count": 67,
      "start_date": "2008-07",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-24",
      "last_synced_at": "2026-09-03T05:21:03.657Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927095"
    }
  ]
}